(Credit-Canva)
The current measles outbreak has gripped US states like Texas and New Mexico leaving people worried whether it would become a new pandemic. According to the Texas Department of State Health Services as of February 21, 90 cases were diagnosed in the last month in the South Plains area, with at least 77 of them were reported in children and teens under 17.
Measles is highly contagious and can be deadly. The outbreak, which started spreading in late January, has resulted in multiple hospitalizations, with at least nine confirmed cases and three probable cases as of early February. Health officials caution that at least one in five infected individuals will have to be hospitalized, highlighting the severity of the situation.
Misinformation surrounding vaccines and with the new Trump administration anti-vaccine campaigs, has causing parents to hesitate or refuse vaccination.
Furthermore, the country down under Australia is also witnessing a surge in measles cases as health officials in Sydney have issued an urgent alert, urging residents to watch for measles symptoms after an infected individual visited several places in Sydney over the last seven days.
Authorities report that the traveller had returned from South East Asia where there are ongoing outbreaks of measles.
Key symptoms of measles include fever, a runny nose, sore eyes, and a cough. Typically, a red, blotchy rash appears three to four days later, spreading from the head down to the body. Symptoms can manifest between 7 and 18 days after exposure.
Anyone who experiences these symptoms after potential exposure should immediately contact their doctor or emergency department. It is crucial to call ahead before visiting to avoid potentially exposing others in the waiting room. Dr. Selvey also highlighted that ongoing measles outbreaks are occurring in various parts of the world, making awareness and prompt action essential.
According to CDC everyone should get the MMR vaccine. It protects you from measles, mumps, and rubella. Getting vaccinated helps stop these diseases from spreading. There are two safe MMR vaccines available. They work the same way, so it doesn't matter which one you get. Kids can also get a shot that protects against chickenpox too, but this is only for children.
All children should get two MMR shots. The first shot should be given when they are between 12 and 15 months old. The second shot should be given when they are between 4 and 6 years old. If needed, the second shot can be given earlier, but it must be at least 28 days after the first shot.
Students going to college or other schools after high school, need two shots if they are not already immune. The shots must be at least 28 days apart.
Most adults need at least one MMR shot. Some adults need two shots, especially those who work in healthcare, travel a lot, or go to college. These people should get two shots, with 28 days between them.
Anyone traveling to other countries should make sure they are protected. Babies 6 to 11 months old should get one shot before traveling. Kids 12 months and older, teens, and adults need two shots, with 28 days between them.
People who work in healthcare should have proof that they are immune to measles, mumps, and rubella. If they are not immune, they need two MMR shots, spaced 28 days apart.
Women who might get pregnant should talk to their doctor about the MMR vaccine. It's safe to get the shot while breastfeeding.
Credit: Canva
New Zealand has stepped up surveillance after the first detection of a dengue and Zika-carrying mosquito larvae in the country.
The larval species was confirmed as 'Aedes aegypti' — known to carry diseases including dengue fever, yellow fever, Zika, and chikungunya, across the globe.
As New Zealand does not normally have the mosquito species, the larvae detected were counted as "exotic".
The mosquito species did not cause any outbreak, but were spotted during a routine surveillance program in Auckland.
"The National Public Health Service has commenced a heightened surveillance and interception programme following mosquito larvae being collected from a routine surveillance trap at Queens Wharf, Auckland, on Monday 30 March," Health New Zealand said in a statement.
Health New Zealand reported that exotic species were occasionally found at ports and airports.
The health body noted that the larvae were not considered a public health or biosecurity threat yet because there was no indication they had become established.
But the agency aimed to continue "intensive monitoring for at least three weeks".
"The monitoring would take place within a 400m radius of the site where the larvae were identified. Health Protection Officers would place mosquito traps in the survey area," the statement said.
"These have been hidden away from plain sight so they are not disturbed, for example, in old tyres, bushes, or pools of water. We ask members of the public to avoid touching or disturbing these traps if they find them, as it may disrupt our monitoring and trapping efforts," medical officer of health Dr David Sinclair said.
Sinclair said New Zealanders were most at risk from diseases transmitted by mosquitoes when travelling overseas, including to Pacific Island countries and territories where dengue fever was known to be present.
The US Centers for Disease Control and Prevention recently issued a travel alert of dengue outbreaks across 17 countries.
The CDC alert issued on March 23 identified 17 countries reporting an increased number of cases of dengue. These include: Afghanistan, Bangladesh, Bolivia, Colombia, Cook Islands, Cuba, Guyana, Maldives, Mali, Mauritania, New Caledonia, Pakistan, Samoa, Sudan, Timor-Leste, Vietnam, and the United States territories of American Samoa, Puerto Rico, and the US Virgin Islands, where local transmission is already common.
Also read: Long-term Exposure To Air Pollution Increases Fatality Rates In Dengue: Study
Dengue is a disease caused by a virus spread through mosquito bites. It is transmitted through infected mosquitoes, primarily the species Aedes aegypti.
The breakbone fever is caused by an infection with any of four different dengue viruses. These include:
• Dengue virus type 1 (DENV-1 or DEN-1)
• Dengue virus type 2 (DENV-2 or DEN-2)
• Dengue virus type 3 (DENV-3 or DEN-3)
• Dengue virus type 4 (DENV-4 or DEN-4)
Also read: New dengue vaccine over 80% effective, prevents severe disease for up to 5 years
Common Symptoms of dengue include:
• Sudden onset of high-grade fever.
• Intense headache
• Severe muscle, joint, or bone pain.
• Skin Rash that often appears 2–5 days after the fever starts
• Nausea and Vomiting
• Minor bleeding
• Fatigue.
Credit: iStock
The COVID Cicada variant, currently circulating in 23 countries, is likely to affect children more than the previous variants.
Children have largely escaped severe illness from the SARS-COV-2 virus.
However, the new Cicada variant with around 75 genetic changes in its spike protein is likely to disproportionately affect children, as per an expert, who noted its presence in the UK.
“Some people have done analysis on this, suggesting it may be more prevalent among young children. Children get infections all the time, but this might be something to do with the fact that they have never been exposed to Covid vaccines," Prof Ravindra Gupta, of Cambridge University, who advised the UK government during the pandemic, was quoted as saying to The Mirror.
“So this is something we’re looking at in the lab to try and work out why. The problem with this is that it is an infection that spreads fast. Eventually, it ends up in someone vulnerable," he added.
Symptoms seem to be similar to those of other recent variants and include
Also read: Cicada Variant: Will The Current COVID Vaccine Provide Protection?
Cicada, a descendant of the Omicron variant that emerged in 2021, was first detected in South Africa in 2024. However, it disappeared soon after, only to emerge early this year.
Prof Gupta told the publication that “the Cicada variant developed the 75 mutations to escape immunity, and it evolved by incubating a single patient for over a year”.
"This 'patient zero' would have been unable to clear the virus due to a compromised immune system," due to HIV or anti-cancer drugs.
Further, he explained that due to 75 mutations to the spike protein, the body’s antibodies will take a longer time to fight the Cicada variant.
However, there is no evidence yet that it is likely to cause more severe disease.
The Cicada variant is particularly concerning as it provides no immune protection to people with previous infection or even vaccination.
Yet, the World Health Organization and health experts advise that existing COVID vaccinations can help prevent severe illness and hospitalization.
"It would appear that all the protections we have from our experience with the virus and with vaccines probably offer more limited—not zero—but more limited protection against this strain," Dr. William Schaffner, professor of infectious diseases at Vanderbilt University Medical Center, was quoted as saying by Time.
Also read: COVID Variant BA.3.2 Spreads To 23 Countries: Is The Variant Under Monitoring A Cause Of Worry?
Dr. Sai Balasubramanian, a doctor and healthcare strategy executive, writing in Forbes, stressed the need to follow COVID practices such as masks and hand hygiene.
"Healthcare professionals recommend taking general precautions, similar to those used to prevent most viral transmission: get vaccinations when appropriate, wear masks in crowded areas or indoors where there is a high risk of transmission," he said.
He also urged “avoid individuals who have known illness or infections, wash hands frequently, and continue to stay apprised of local community guidelines and the infection spread”.
Credit: iStock
GLP-1 drugs are powerful tools that can improve health, but it comes with risks and caveats. While these are medical therapies, they are being misused as cosmetic products by cosmetologists, physiotherapists, dermatologists, among others.
To curb its misuse and improve public health, the Indian government today issued guidelines on its use, while also flagging risks around it.
In an official statement issued today, the government has stated that it will roll out stricter inspections to curb the misuse of GLP-1 drugs in the country and will punish those who violate the rules.
“GLP-1 drugs are a significant medical breakthrough in treating type 2 diabetes and obesity, but they are not without risk. The drugs carry a wide range of side effects - from common symptoms like nausea and vomiting to severe complications including pancreatitis, kidney injury, and bowel obstruction. These risks make it essential that GLP-1 drugs are only taken under the supervision of registered medical practitioners/specialists,” the statement said.
In the wake of its hype over weight loss, the country's regulatory authorities have taken firm steps to prevent unsupervised use and malpractices in the supply chain.
It has “strongly advised” patients and the public to” consult a qualified medical specialist before use, and to obtain these medications with prescription only through legitimate, regulated channels”.
“Stricter inspections and surveillance will continue in the coming weeks. Businesses that break the rules will face license cancellation, fines, and legal action,” the statement said.
Also read: GLP-1 Drugs: Why India Needs Stricter Rules Now
GLP-1 drugs work to keep food in the digestive system for longer – making people feel fuller for longer, thus reducing appetite and inducing weight loss. Hence, the drugs are also prescribed to people with obesity.
However, when done without clinical oversight, it can lead to severe health complications.

There are various side effects to taking GLP-1 drugs, including nausea and dizziness, to pancreatitis and medullary thyroid cancer.
Some serious side effects include

GLP-1 medications may also complicate various health conditions, such as allergic reactions, with shortness of breath and low blood sugar.
The government's advisory comes as patent for semaglutide -- an active ingredient in diabetes and anti-obesity drugs, specifically Wegovy and Ozempic -- expired on March 20.
This has led to a rush among Indian pharma companies to launch cheaper generic versions, significantly increasing affordability and access for millions battling Type 2 diabetes and obesity.
Also read: CDSCO threatens action against pharma companies for promoting GLP-1 weight-loss drugs
Major Indian drugmakers who launched their generic semglutide injection in the country in March include Sun Pharmaceutical Industries, Zydus Lifesciences, Alkem Laboratories, and Dr. Reddy’s Laboratories.
Amid the increasing prevalence of GLP-1 drugs, the World Health Organisation (WHO), late last year, acknowledged its role in treating obesity.
However, it warned that medications like GLP-1 alone will not solve the problem affecting more than one billion people worldwide.
The global health body also issued conditional recommendations for using these therapies as part of a comprehensive approach that includes healthy diets, regular physical activity, and support from health professionals.
© 2024 Bennett, Coleman & Company Limited